Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

14.99USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$14.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
274,690
52-wk High
$43.85
52-wk Low
$11.89

Porter, Derrell 

Dr. Derrell D. Porter, M.D. has served as our Senior Vice President,Head of Commercial of the Company. He has served as our Chief Financial Officer since June 2018. Prior to joining Atara, from June 2011 to June 2018, Mr. Koppikar held several senior financial leadership positions at Gilead Sciences, including as Vice President of Corporate and Operations Finance, responsible for R&D, corporate, G&A, process development and manufacturing, and strategic sourcing. Prior to Gilead, from January 2001 to June 2011, he served in multiple finance roles of increasing responsibility at Amgen. Mr. Koppikar earned his B.S. in aerospace engineering at the University of Maryland and received a M.S. in aeronautical and astronautical engineering from Stanford University. He also holds an MBA in finance and marketing from The Anderson School at UCLA.

Basic Compensation

Total Annual Compensation, USD 457,457
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,052,940
Fiscal Year Total, USD 1,510,390

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Pascal Touchon

--

Utpal Koppikar

4,220,280

Joseph Newell

2,492,290

Mina Kim

3,384,430

Derrell Porter

1,510,390

Dietmar Berger

4,972,440
As Of  31 Dec 2018